Surgical Collaboration: Unlocking HS Treatment Potential
The 10th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA) unveiled a transformative approach to managing Hidradenitis Suppurativa (HS). Ralph George, MD, FRCS, a renowned surgical oncologist, highlighted the pivotal role of collaboration between medical and surgical management in enhancing HS treatment outcomes across all disease stages.
In his presentation, George emphasized that the evolving partnership between medical and surgical interventions is redefining the efficacy of HS procedures. As an associate professor and director of the CPD Department of Surgery at the University of Toronto, George shared insights from his session, 'Procedural Interventions Across the Spectrum of HS,' at the SHSA.
George's key message: surgery is becoming increasingly effective in HS treatment, not solely due to the skills of surgeons, but because complementary treatments are significantly improving. This synergy allows surgery to play an even more substantial role in managing HS. He stressed that surgery is not mandatory but can be highly beneficial at various stages of HS, even for mild, localized cases.
The session also shed light on the latest research and advancements in HS. George noted the rapid pace of progress in the field, making it challenging to keep up. He attributed this excitement to bench research and clinical trials, which are driving surgeons to innovate and improve their ability to tackle HS more effectively.
The value of disease-specific meetings like SHSA was another critical aspect. George praised the unique atmosphere of the SHSA, where a diverse group of professionals, including PhD molecular biologists, patients, surgeons, and dermatologists, come together. This interdisciplinary approach, he believes, enriches everyone involved and fosters a collaborative spirit.
Looking ahead, George expressed optimism about the future of HS treatment. He envisioned a scenario where surgery's role in HS might diminish, similar to breast cancer, as advancements in other treatment modalities take precedence. However, he welcomed this evolution, indicating that it would ultimately benefit patients.
For those interested in staying updated, Dermatology Times offers a valuable resource. Subscribers can receive weekly newsletters featuring the latest therapies, innovations, and practical tips for real-world HS management.
